This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.




2f8g

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2f8g.gif|left|200px]]
+
{{Seed}}
 +
[[Image:2f8g.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2f8g| PDB=2f8g | SCENE= }}
{{STRUCTURE_2f8g| PDB=2f8g | SCENE= }}
-
'''HIV-1 protease mutant I50V complexed with inhibitor TMC114'''
+
===HIV-1 protease mutant I50V complexed with inhibitor TMC114===
-
==Overview==
+
<!--
-
The potent new antiviral inhibitor TMC-114 (UIC-94017) of HIV-1 protease (PR) has been studied with three PR variants containing single mutations D30N, I50V, and L90M, which provide resistance to the major clinical inhibitors. The inhibition constants (K(i)) of TMC-114 for mutants PR(D30N), PR(I50V), and PR(L90M) were 30-, 9-, and 0.14-fold, respectively, relative to wild-type PR. The molecular basis for the inhibition was analyzed using high-resolution (1.22-1.45 A) crystal structures of PR mutant complexes with TMC-114. In PR(D30N), the inhibitor has a water-mediated interaction with the side chain of Asn30 rather than the direct interaction observed in PR, which is consistent with the relative inhibition. Similarly, in PR(I50V) the inhibitor loses favorable hydrophobic interactions with the side chain of Val50. TMC-114 has additional van der Waals contacts in PR(L90M) structure compared to the PR structure, leading to a tighter binding of the inhibitor. The observed changes in PR structure and activity are discussed in relation to the potential for development of resistant mutants on exposure to TMC-114.
+
The line below this paragraph, {{ABSTRACT_PUBMED_16480273}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 16480273 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_16480273}}
==About this Structure==
==About this Structure==
Line 26: Line 30:
[[Category: Weber, I T.]]
[[Category: Weber, I T.]]
[[Category: Hiv-1 protease-inhibitor complex]]
[[Category: Hiv-1 protease-inhibitor complex]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 03:35:18 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Jul 27 18:08:53 2008''

Revision as of 15:09, 27 July 2008

Image:2f8g.png

Template:STRUCTURE 2f8g

HIV-1 protease mutant I50V complexed with inhibitor TMC114

Template:ABSTRACT PUBMED 16480273

About this Structure

2F8G is a Single protein structure of sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.

Reference

Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M., Kovalevsky AY, Tie Y, Liu F, Boross PI, Wang YF, Leshchenko S, Ghosh AK, Harrison RW, Weber IT, J Med Chem. 2006 Feb 23;49(4):1379-87. PMID:16480273

Page seeded by OCA on Sun Jul 27 18:08:53 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2f8g"
Personal tools